Anti-fibrillation and trans-fibrillation activities of L-arginine modified magnetic nanoparticles on lysozyme

Read full text Summarise with VIRAT
Authors: Vahid Alimohammadi, Fatemeh Eshari, Faezeh Kashanian, Ali Akbar Moosavi‐Movahedi, Seyd Ali Seyed-Ebrahimi, Mehran Habibi-Rezaei
Cited by: 0
References: 42

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Over the last two decades, the application of nanoparticles (NPs) in the investigation of protein and peptide aggregation and amyloid-related diseases has been extensively studied. Here, we investigate anti-fibrillation and trans -fibrillation activities of L -Arginine modified Magnetic NPs (RMNPs, Fe 3 O 4 @Arg) on hen egg white lysozyme (HEWL) as a model protein and HEWL amyloid aggregate (HAA, i.e., aggregated HEWL fibrils). RMNPs were prepared by the co-precipitation method and subsequently characterized using X-ray diffraction (XRD), vibrating sample magnetometry (VSM), Fourier transform infrared spectroscopy (FT-IR), and scanning electron microscopy (SEM). The comparison was made among Arg, Magnetic NPs (MNPs), and RMNPs to explore their anti-fibrillation activities on HEWL. Using intrinsic tryptophan (Trp) and extrinsic thioflavin T (ThT) fluorescence assays, circular dichroism (CD) spectroscopy, and electron microscopy methods, for instance, we present the anti-fibrillation and trans -fibrillation activities of the RMNPs on HEWLs or HAAs. Accordingly, fibrillation was inhibited more than 80 percent, and fibrils were longitudinally rearranged to form late amyloid aggregates with a 57< nm diameter from early aggregates with a

Fields of Study & Subjects

Alzheimer's disease research and treatments Prion Diseases and Protein Misfolding Protein purification and stability

Publication details

Journal / source
Biochemistry and Biophysics Reports
Volume
46
Pages
102551–102551
Publication date
23 March 2026
Language
EN